{
    "doi": "https://doi.org/10.1182/blood.V110.11.3049.3049",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=946",
    "start_url_page_num": 946,
    "is_scraped": "1",
    "article_title": "Graft-Versus-Leukemia Effect Is Equivalent in Recipients of Matched Sibling and Matched Unrelated Donor Conventional Hematopoietic Cell Transplant. ",
    "article_date": "November 16, 2007",
    "session_type": "Clinical Results - Alternative Donor Transplantation",
    "topics": [
        "donors",
        "hematopoietic stem cell transplantation",
        "leukemia",
        "relationship - sibling",
        "tissue transplants",
        "human leukocyte antigens",
        "disease remission",
        "transplantation, homologous",
        "accelerated phase",
        "blast phase"
    ],
    "author_names": [
        "Mukta Arora, MD, MS",
        "Steven Pavletic, MD, PhD",
        "Claudio Anasetti, MD",
        "John Barrett, MD, MRCP",
        "Tao Wang, PhD",
        "Joseph H. Antin, MD",
        "Paolo Di Bartolomeo, MD",
        "Brian J. Bolwell, MD",
        "Christopher Bredeson, MD",
        "Mitchell Cairo, MD",
        "Robert P. Gale, MD, PhD",
        "Sergio Giralt, MD",
        "Theresa Hahn, MD",
        "Gregory Hale, MD",
        "Joerg Halter, MD",
        "Madan Jagasia, MD",
        "Mark R. Litzow, MD",
        "Franco Locatelli, MD",
        "Phillip L. McCarthy, MD",
        "Cowan Mort, MD",
        "Effie W. Petersdorf, MD",
        "James Russel, MD",
        "Gary Schiller, MD",
        "Harry S. Schouten, MD, PhD",
        "Martin Tallman, MD",
        "Leo F. Verdonck, MD",
        "Joseph Wiley, MD",
        "John R. Wingard, MD",
        "Mary M. Horowitz, MD, MS",
        "Olle Ringden, MD, PhD"
    ],
    "author_affiliations": [
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ],
        [
            "On Behalf of the Writing Committee, Center for International Blood & Marrow Transplant (CIBMTR), Milwaukee, WI, USA"
        ]
    ],
    "first_author_latitude": "43.0435728",
    "first_author_longitude": "-88.02116509999999",
    "abstract_text": "Anti-leukemia effects of allotransplants are largely mediated by immune mechanisms collectively termed graft-versus-leukemia (GvL). We postulated that allotransplants from HLA-matched unrelated donors (URD) have greater GvL activity than similar transplants from HLA-identical siblings because of greater genetic-disparity between donor and recipient. We tested this hypothesis in 4099 adult recipients of HLA-matched sibling (N= 3158) or 8/8 HLA-allele-matched URD (N= 941) transplants for acute leukemia (AML and ALL) and chronic myeloid leukemia (CML) receiving conventional transplants between 1995\u20132004 and reported to CIBMTR. Relapse, transplant-related mortality (TRM) and leukemia-free survival (LFS) were compared between the cohorts. Contrary to our hypothesis, relapse rates at 5 y were similar in patients receiving sibling and URD transplants. More TRM was seen in URD cohort in early AML [sibs 24% (20\u201327%) versus URD 40% (31\u201350%), p=0.001], advanced ALL or AML [sibs 31% (25\u201336%) versus URD 44% (35\u201353%), p= 0.01] and early CML [sibs 31% (28\u201333%) versus 38% (32\u201344%), p=0.02]. LFS was superior with sibling donors in early- and advanced- AML and CML. These data indicate comparable GvL-activity of HLA matched URD and HLA-identical sibling transplants in AML, ALL and CML receiving conventional transplants despite greater genetic disparity.  Early Disease (1 st remission or 1 st chronic phase) . Outcome at 5 years . Sibling donor . URD . P . AML (N= 878) 760 118  Relapse 15 (13\u201318)% 22 (15\u201330)% 0.1 LFS 61 (57\u201365)% 38 (28\u201348)% <0.001 ALL (N= 333) 271 62  Relapse 23 (18\u201329)% 15 (7\u201325)% 0.13 LFS 46 (39\u201353)% 42 (29\u201355)% 0.6 CML (N=1443) 1152 291  Relapse 6 (5\u20138)% 5 (3\u20138)% 0.5 LFS 63 (60\u201366)% 57 (51\u201363)% 0.06 Intermediate Disease (2nd or subsequent remission or accelerated phase) AML (N= 268) 180 88  Relapse 22 (16\u201329)% 21 (13\u201330)% 0.8 LFS 48 (40\u201356)% 41 (30\u201352)% 0.3 ALL (N= 172) 111 61  Relapse 32 (24\u201342)% 36 (24\u201348)% 0.7 LFS 27 (18\u201336)% 24 (14\u201337)% 0.8 CML (N=263) 173 90  Relapse 22 (15\u201328)% 16 (9\u201324)% 0.5 LFS 36 (29\u201344)% 35 (26\u201346)% 0.9 Advanced Disease (Not in remission or blast phase) AML (N= 423) 294 129  Relapse 46 (40\u201352)% 43 (34\u201351)% 0.6 LFS 23 (18\u201329)% 13 (8\u201320)% 0.01 ALL (N= 152) 88 64  Relapse 52 (42\u201363)% 48 (35\u201360)% 0.6 LFS 10 (4\u201318)% 5 (1\u201312)% 0.2 CML (N=76) 49 27  Relapse 35 (23\u201349)% 39 (20\u201360)% 0.8 LFS 21 (11\u201335)% 0 <0.001 Early Disease (1 st remission or 1 st chronic phase) . Outcome at 5 years . Sibling donor . URD . P . AML (N= 878) 760 118  Relapse 15 (13\u201318)% 22 (15\u201330)% 0.1 LFS 61 (57\u201365)% 38 (28\u201348)% <0.001 ALL (N= 333) 271 62  Relapse 23 (18\u201329)% 15 (7\u201325)% 0.13 LFS 46 (39\u201353)% 42 (29\u201355)% 0.6 CML (N=1443) 1152 291  Relapse 6 (5\u20138)% 5 (3\u20138)% 0.5 LFS 63 (60\u201366)% 57 (51\u201363)% 0.06 Intermediate Disease (2nd or subsequent remission or accelerated phase) AML (N= 268) 180 88  Relapse 22 (16\u201329)% 21 (13\u201330)% 0.8 LFS 48 (40\u201356)% 41 (30\u201352)% 0.3 ALL (N= 172) 111 61  Relapse 32 (24\u201342)% 36 (24\u201348)% 0.7 LFS 27 (18\u201336)% 24 (14\u201337)% 0.8 CML (N=263) 173 90  Relapse 22 (15\u201328)% 16 (9\u201324)% 0.5 LFS 36 (29\u201344)% 35 (26\u201346)% 0.9 Advanced Disease (Not in remission or blast phase) AML (N= 423) 294 129  Relapse 46 (40\u201352)% 43 (34\u201351)% 0.6 LFS 23 (18\u201329)% 13 (8\u201320)% 0.01 ALL (N= 152) 88 64  Relapse 52 (42\u201363)% 48 (35\u201360)% 0.6 LFS 10 (4\u201318)% 5 (1\u201312)% 0.2 CML (N=76) 49 27  Relapse 35 (23\u201349)% 39 (20\u201360)% 0.8 LFS 21 (11\u201335)% 0 <0.001 View Large"
}